Unknown

Dataset Information

Using Informatics Tools to Identify Opportunities for Precision Medicine in Diffuse Large B-cell Lymphoma.


ABSTRACT:

Introduction

Diffuse large B-cell lymphoma (DLBCL) is genetically and clinically heterogeneous. Despite advances in genomic subtyping, standard frontline chemoimmunotherapy has remained unchanged for years. As high-throughput analysis becomes more accessible, characterizing drug-gene interactions in DLBCL could support patient-specific treatment strategies.

Materials and methods

From our systematic literature review, we compiled a comprehensive list of somatic mutations implicated in DLBCL. We extracted reported and primary sequencing data for these mutations and assessed their association with signaling pathways, cell-of-origin subtypes, and clinical outcomes.

Results

Twenty-two targetable mutations present in ≥ 5% of patients with DLBCL were associated with unfavora

SUBMITTER: Patel SP 

PROVIDER: S-EPMC7136133 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature